| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1016/0006-3223(95)00049-7 |
| P8608 | Fatcat ID | release_druh6hpuwrbd5dj7zzkm66hzlq |
| P698 | PubMed publication ID | 8573660 |
| P50 | author | Augustus John Rush | Q21104277 |
| Madhukar Trivedi | Q87600331 | ||
| P2093 | author name string | Fulton M | |
| Petty F | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 578-591 | |
| P577 | publication date | 1995-11-01 | |
| P1433 | published in | Biological Psychiatry | Q4914961 |
| P1476 | title | Benzodiazepines as antidepressants: does GABA play a role in depression? | |
| P478 | volume | 38 |
| Q40110351 | A Pharmacogenetic 'Restriction-of-Function' Approach Reveals Evidence for Anxiolytic-Like Actions Mediated by α5-Containing GABAA Receptors in Mice |
| Q41449783 | Alprazolam as a monotherapy for anxiety and depression. |
| Q24201994 | Alprazolam for depression |
| Q24243427 | Alprazolam for depression |
| Q46619353 | Alprazolam potentiates the antiaversive effect induced by the activation of 5-HT(1A) and 5-HT (2A) receptors in the rat dorsal periaqueductal gray |
| Q92849602 | Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments |
| Q30887852 | Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants |
| Q43597628 | Antidepressant-like actions of pregnancy, and progesterone in Wistar rats forced to swim |
| Q34504773 | Antidepressant-like properties of α2-containing GABAA receptors |
| Q35924378 | Anxiety and depression: mouse genetics and pharmacological approaches to the role of GABA(A) receptor subtypes |
| Q34415535 | Anxiety disorders and major depression, together or apart |
| Q90288858 | Astrocytic GABAB Receptors in Mouse Hippocampus Control Responses to Behavioral Challenges through Astrocytic BDNF |
| Q24234568 | Benzodiazepines and related drugs for older depressed people |
| Q30466591 | Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes |
| Q33231128 | Beyond monoamines: glutamatergic function in mood disorders |
| Q35017636 | Bipolar depression: management options |
| Q91641482 | Brexanolone, a neurosteroid antidepressant, vindicates the GABAergic deficit hypothesis of depression and may foster resilience |
| Q34300348 | Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature. |
| Q64102147 | Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions |
| Q30421954 | Diversity of neuronal inhibition: a path to novel treatments for neuropsychiatric disorders. |
| Q64971370 | ERβ agonist alters RNA splicing factor expression and has a longer window of antidepressant effectiveness than estradiol after long-term ovariectomy |
| Q44255920 | Effects of single and combined gabapentin use in elevated plus maze and forced swimming tests |
| Q73688558 | Effects of tricyclic and tetracyclic antidepressants on the three subtypes of GABA transporter |
| Q37800213 | Evidence for GABAergic inhibitory deficits in major depressive disorder |
| Q40840213 | GABA function in mood disorders: an update and critical review |
| Q48678920 | GABA(A) receptor beta 3 subunit gene and psychiatric morbidity in a post-traumatic stress disorder population |
| Q73120053 | GABA(B) receptor mechanism and imipramine-induced antinociception in ligated and non-ligated mice |
| Q30421260 | GABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism |
| Q36668325 | GABAergic control of depression-related brain states |
| Q35187929 | GABAergic dysfunction in mood disorders. |
| Q35884948 | GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia |
| Q73458645 | Growth hormone response to the GABAB agonist baclofen in major depressive disorder |
| Q48339550 | Hippocampal GABAergic dysfunction in a rat chronic mild stress model of depression |
| Q41700928 | Identification of a novel, fast-acting GABAergic antidepressant |
| Q91087662 | Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant |
| Q37650420 | Impaired GABA synthesis, uptake and release are associated with depression-like behaviors induced by chronic mild stress |
| Q36950569 | Incoordination among Subcellular Compartments Is Associated with Depression-Like Behavior Induced by Chronic Mild Stress |
| Q48712752 | Involvement of diazepam-insensitive benzodiazepine receptors in the suppression of DOI-induced head-twitch responses in diabetic mice |
| Q38488288 | Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression? |
| Q90631290 | Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives |
| Q47613909 | Mechanism of triazolo-benzodiazepine and benzodiazepine action in anxiety and depression: behavioral studies with concomitant in vivo CA1 hippocampal norepinephrine and serotonin release detection in the behaving animal |
| Q37960095 | Modulation of ion channels in clinical psychopharmacology: adults and younger people |
| Q48786821 | Pharmacologic treatments effective in both generalized anxiety disorder and major depressive disorder: clinical and theoretical implications |
| Q44714343 | Possible association between a haplotype of the GABA-A receptor alpha 1 subunit gene (GABRA1) and mood disorders |
| Q34847665 | Progesterone and neurology |
| Q28140526 | Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents |
| Q33802572 | Reduced level of glutamic acid decarboxylase-67 kDa in the prefrontal cortex in major depression. |
| Q34583254 | Role of GABA in anxiety and depression |
| Q38495104 | Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression |
| Q39429092 | Somatostatin-Positive Gamma-Aminobutyric Acid Interneuron Deficits in Depression: Cortical Microcircuit and Therapeutic Perspectives |
| Q57244300 | Still no evidence that benzodiazepines cause depression |
| Q37100602 | The Effect of Chronic Alprazolam Intake on Memory, Attention, and Psychomotor Performance in Healthy Human Male Volunteers |
| Q30464954 | The GABAergic deficit hypothesis of major depressive disorder. |
| Q37196318 | The ability of BDNF to modify neurogenesis and depressive-like behaviors is dependent upon phosphorylation of tyrosine residues 365/367 in the GABA(A)-receptor γ2 subunit |
| Q52128583 | The influence of gender and the estrous cycle on learned helplessness in the rat. |
| Q35202929 | The neurobiology and control of anxious states |
| Q58780469 | The protective effects of ethanolic extract of Clematis terniflora against corticosterone-induced neuronal damage via the AKT and ERK1/2 pathway |
| Q38837135 | The solvation structure of alprazolam |
| Q44348855 | Two types of classification for male opioid dependence: identification of an opioid addict with depressive features |
| Q45046922 | Use of benzodiazepines, depressive symptoms and cognitive function in old age. |
| Q34295813 | α2-containing GABA(A) receptors: a target for the development of novel treatment strategies for CNS disorders. |
Search more.